<DOC>
	<DOC>NCT01098500</DOC>
	<brief_summary>A retrospective cohort study using the LabRx medical claims database will be performed to address these objectives. The primary objective of this project is to examine the background rates of liver function test (LFT) abnormalities in cancer patients treated with tyrosine kinase inhibitors (TKIs).</brief_summary>
	<brief_title>Liver Function Test (LFT) Elevations in Cancer Patients and Users of Tyrosine Kinase Inhibitor (TKI) Drugs</brief_title>
	<detailed_description>Patients were not recruited for nor enrolled in this study. This study is a retrospective observational study. Data from medical records or insurance claims databases are anonymised and used to develop a patient cohort. All diagnoses and treatment are recorded in the course of routine medical practice.</detailed_description>
	<criteria>Adult (age â‰¥18 years) with at least two ICD9 codes for a particular cancer (ICD9 code 140208.9) within a 6 month timeframe and at least one code for a TKI drug that occurs on or after the first cancer diagnosis code At least one month (30 days) of enrolment prior to index date and three months (91 days) of followup post index date; and Continuous enrolment in the LabRx database during followup. Less than 18 years old Less than one month (30 days) of enrolment prior to index date or three months (91 days) of followup post index date; and Not continuously enrolled in the LabRx database during followup.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Liver function</keyword>
	<keyword>Tyrosine Kinase Inhibitor</keyword>
</DOC>